Comparing Two Antibiotics for Blood Infection in Cancer Patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two antibiotics (ceftolozane/tazobactam vs. piperacillin/tazobactam) for treating a bloodstream infection in people with blood cancer who have a very low white blood cell count and a fever. The goal is to see which antibiotic works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a blood cancer (like leukemia, lymphoma, or myeloma).
- You have a very low count of neutrophils (a type of white blood cell) — less than 500 per cubic millimeter.
- You have a fever (101°F or higher once, or 100.4°F or higher on two separate checks).
- Your blood pressure is stable (the bottom number is at least 65 mmHg).
- You are expected to live at least 5 more days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well an antibiotic called ceftazidime-avibactam (CAZ-AVI) works in people with blood cancers or those who have had a stem cell transplant. It aims to find the right dose and see if the bacteria become resistant.
This trial compares two antibiotics, ciprofloxacin and ceftazidime, to see which works better for treating fever in children with blood cancer who have a high risk of infection due to low white blood cells. The goal is to find the best treatment to help your child recover faster.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
Hear when a new Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.